TAG'D: Beyond The Award
On this episode of TAG’D: Beyond the Award, Justin Starbird sits down with Dr. Helen Reeve Stoffer [https://www.linkedin.com/in/helen-reeve-stoffer-352a361/], Chief Operating Officer of Recor Medical [https://www.recormedical.com/]'s, to unpack the extraordinary 14-year journey behind the Paradise™ Ultrasound Renal Denervation System, winner of the 2026 TAG Award for Cardiovascular Therapeutic Innovation [https://www.tagawards.co/medtech-26/recor-medical/]. What began as a bold idea to treat hypertension with ultrasound technology became one of the most resilient comeback stories in modern MedTech. After a devastating industry-wide clinical trial failure nearly derailed renal denervation entirely, Recor refused to walk away. Instead, the team rebuilt the clinical playbook from the ground up, partnered with leading hypertension experts, and helped prove that device-based therapy could become a viable new option for millions of patients living with uncontrolled high blood pressure. The conversation dives into the realities of bringing category-defining technology to market, the persistence required to survive in MedTech, and why hypertension remains one of the world’s most urgent healthcare challenges. With more than 100 million Americans affected by high blood pressure, Recor’s mission extends far beyond innovation. It is about giving patients another path forward against one of healthcare’s most dangerous “silent killers.” Released alongside World Hypertension Day [https://www.who.int/news-room/events/detail/2026/05/17/default-calendar/world-hypertension-day-2026] on May 17, this episode is also a reminder of the importance of awareness, prevention, and expanding access to new treatment options for patients worldwide. From startup uncertainty to commercial success, this is a story about science, resilience, leadership, and the long road to changing patient lives.
29 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de TAG'D: Beyond The Award!